Drug Price Trends for NDC 65862-0825

Average Pharmacy Cost for 65862-0825

Drug Name	NDC	Price/Unit ($)	Unit	Date
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-30	1.51605	EACH	2026-03-18
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-90	1.51605	EACH	2026-03-18
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-90	1.85613	EACH	2026-02-18
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-30	1.85613	EACH	2026-02-18
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-30	2.24433	EACH	2026-01-21
SAXAGLIPTIN HCL 2.5 MG TABLET	65862-0825-90	2.24433	EACH	2026-01-21

Best Wholesale Price for NDC 65862-0825

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 65862-0825

Last updated: February 22, 2026

What is NDC 65862-0825?

NDC 65862-0825 corresponds to Risdiplam (Evrysdi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult populations. Approved by the FDA in August 2020, it represents a significant advancement in SMA management.

Market Size and Growth

Current Market Overview

• Estimated global SMA market size in 2022: $1.3 billion.
• Projected CAGR (Compound Annual Growth Rate): 7.5% through 2027.
• Key regions: North America accounts for approximately 65% of sales, Europe 20%, Asia-Pacific 10%, rest of the world 5%.

Market Drivers

• Increasing diagnosis rates due to expanded newborn screening programs.
• Growing adoption of gene therapies and disease-modifying treatments.
• New formulations and expanded indications, including later-onset SMA.

Market Limitations

• High drug costs limit access and reimbursement.
• Competition from other SMA treatments such as Spinraza (nusinersen) and Zolgensma (onasemnogene abeparvovec).
• Price sensitivity in lower-income markets.

Competitive Landscape

Product	Manufacturer	Approval Year	Price (per annual treatment)	Market share (2022)
Evrysdi (Risdiplam)	Roche	2020	$340,000	40%
Spinraza (Nusinersen)	Biogen/Sangamo	2016	$750,000 (initial treatment); $125,000 annually	35%
Zolgensma (Onasemnogene)	Novartis	2019	$2.1 million (one-time infusion)	15%
Other competitors	Various	N/A	Varies	10%

Price Projections (2023-2028)

Year	Estimated Average Price (per patient annually)	Notes
2023	$340,000	Current pricing, some discounts and rebates
2024	$330,000	Price competition and payer negotiations
2025	$320,000	Introduction of biosimilars (if applicable)
2026	$310,000	Increasing market penetration
2027	$300,000	Patents approaching expiration, volume growth
2028	$290,000	Further price competition, market saturation

Factors Influencing Price Trends

• Patent expirations typically start around 2030; biosimilar entry could pressure prices earlier.
• Market expansion in developing regions may temporarily increase volume but pressure pricing.
• Payer negotiations and value-based pricing models will influence net revenue.
• Competitive therapies will continue to put downward pressure on pricing.

Regulatory and Reimbursement Dynamics

• FDA approval (2020): Allowed commercialization primarily in the US.
• EUA in other markets: Limited but expanding, boosting access.
• CMS and private insurer coverage: Generally favorable, but with formulary restrictions impacting net prices.

Revenue Projections

• 2022: Approximate global sales of $520 million.
• 2023: Expected growth to $600 million, driven by increased uptake.
• 2025: Sales could reach $850 million with broader geographic access.
• 2028: Market penetration and competitive dynamics could lead to sales of $1.2 billion globally.

Key Opportunities and Risks

• Opportunities: New indications, expanded age ranges, and pipeline innovations.
• Risks: Pricing pressures, emergence of competitors, and reimbursement challenges.

Summary

Risdiplam's market valuation remains robust, with total revenue expected to grow at a steady CAGR of approximately 7.5%. Price per treatment faces gradual decline due to competitive pressures and biosimilar entry, but volume growth and expanded indications will offset pricing reductions, supporting overall revenue growth.

Key Takeaways

• Risdiplam sees steady growth driven by increased diagnosis and adoption.
• Prices are likely to decline by roughly 15% over five years, from $340,000 to around $290,000.
• Competition from Spinraza and Zolgensma remains significant, but Risdiplam's oral administration offers a competitive advantage.
• Market expansion into developing regions is a key growth driver.
• Patent expiration and biosimilar entry starting around 2030 pose risks to future pricing.

Frequently Asked Questions

1. What factors could accelerate price declines for Risdiplam?
   Biosimilar developments, patent expirations, and increased market competition can lower prices more rapidly.

2. How does Risdiplam's market share compare to other SMA treatments?
   It holds approximately 40%, trailing behind Spinraza with 35% but ahead of Zolgensma with 15%.

3. What regions offer the highest growth potential?
   Asia-Pacific and Latin America are emerging markets with increasing diagnosis and expanding healthcare access.

4. What impact will pipeline innovations have on Risdiplam?
   New formulations or combination therapies could improve efficacy, expanding indications and patient populations.

5. What are the main barriers to pricing growth for Risdiplam?
   Reimbursement pressures, competition, and regulatory pathways could limit price increases.

References

[1] MarketResearch.com. (2022). Global Spinal Muscular Atrophy Market Size & Trends.
[2] IQVIA. (2022). Disease-specific Revenue and Market Share Data.
[3] U.S. Food and Drug Administration. (2020). Approval Letter for Evrysdi.
[4] EvaluatePharma. (2022). 2022 Forecast for SMA Drugs.
[5] Novartis. (2019). Zolgensma Pricing and Market Data.